JP6556225B2 - Ｍｋ２阻害剤およびその使用 - Google Patents

Ｍｋ２阻害剤およびその使用 Download PDF

Info

Publication number
JP6556225B2
JP6556225B2 JP2017515845A JP2017515845A JP6556225B2 JP 6556225 B2 JP6556225 B2 JP 6556225B2 JP 2017515845 A JP2017515845 A JP 2017515845A JP 2017515845 A JP2017515845 A JP 2017515845A JP 6556225 B2 JP6556225 B2 JP 6556225B2
Authority
JP
Japan
Prior art keywords
aliphatic
compound
disease
optionally substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529367A5 (enExample
JP2017529367A (ja
Inventor
マシュー デイビッド アレキサンダー，
マシュー デイビッド アレキサンダー，
クラウディオ チュアキ，
クラウディオ チュアキ，
ジョン マローナ，
ジョン マローナ，
ジョセフ ジョン マクドナルド，
ジョセフ ジョン マクドナルド，
ヤイク ニー，
ヤイク ニー，
デチャン ニュー，
デチャン ニュー，
ラッセル シー． ペッター，
ラッセル シー． ペッター，
ジャスウィンダー シン，
ジャスウィンダー シン，
チタリ パッバ，
チタリ パッバ，
Original Assignee
セルジーン シーエーアール エルエルシー
セルジーン シーエーアール エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルジーン シーエーアール エルエルシー, セルジーン シーエーアール エルエルシー filed Critical セルジーン シーエーアール エルエルシー
Publication of JP2017529367A publication Critical patent/JP2017529367A/ja
Publication of JP2017529367A5 publication Critical patent/JP2017529367A5/ja
Application granted granted Critical
Publication of JP6556225B2 publication Critical patent/JP6556225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2017515845A 2014-09-17 2015-09-16 Ｍｋ２阻害剤およびその使用 Active JP6556225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019127476A Division JP2019194236A (ja) 2014-09-17 2019-07-09 Ｍｋ２阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2017529367A JP2017529367A (ja) 2017-10-05
JP2017529367A5 JP2017529367A5 (enExample) 2018-10-25
JP6556225B2 true JP6556225B2 (ja) 2019-08-07

Family

ID=55454109

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515845A Active JP6556225B2 (ja) 2014-09-17 2015-09-16 Ｍｋ２阻害剤およびその使用
JP2019127476A Pending JP2019194236A (ja) 2014-09-17 2019-07-09 Ｍｋ２阻害剤およびその使用
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Ｍｋ２阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019127476A Pending JP2019194236A (ja) 2014-09-17 2019-07-09 Ｍｋ２阻害剤およびその使用
JP2022041396A Active JP7375072B2 (ja) 2014-09-17 2022-03-16 Ｍｋ２阻害剤およびその使用

Country Status (30)

Country Link
US (5) US9458175B2 (enExample)
EP (2) EP3912981A1 (enExample)
JP (3) JP6556225B2 (enExample)
KR (1) KR102457848B1 (enExample)
CN (1) CN106998692B (enExample)
AU (1) AU2015317741B2 (enExample)
BR (1) BR112017005266B1 (enExample)
CA (1) CA2961607C (enExample)
CL (1) CL2017000576A1 (enExample)
CO (1) CO2017003279A2 (enExample)
CY (1) CY1124215T1 (enExample)
DK (1) DK3193611T3 (enExample)
EA (1) EA037299B1 (enExample)
EC (1) ECSP17023281A (enExample)
ES (1) ES2874561T3 (enExample)
HR (1) HRP20210529T1 (enExample)
HU (1) HUE054347T2 (enExample)
IL (1) IL251051B (enExample)
LT (1) LT3193611T (enExample)
MA (1) MA40534B1 (enExample)
MX (2) MX373341B (enExample)
PL (1) PL3193611T3 (enExample)
PT (1) PT3193611T (enExample)
RS (1) RS62017B1 (enExample)
SA (1) SA517381115B1 (enExample)
SG (2) SG11201701861RA (enExample)
SI (1) SI3193611T1 (enExample)
SM (1) SMT202100311T1 (enExample)
TW (1) TWI744217B (enExample)
WO (1) WO2016044463A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596086A4 (en) * 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP7692353B2 (ja) * 2018-10-02 2025-06-13 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
US12594277B2 (en) 2020-02-14 2026-04-07 Salk Institute For Biological Studies Macrocyclic ULK1/2 inhibitors
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
WO2022020562A1 (en) * 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CA3201774A1 (en) * 2020-11-12 2022-05-19 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
US12668598B2 (en) 2022-10-27 2026-06-30 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
KR20250139398A (ko) * 2023-02-07 2025-09-23 셀진 코포레이션 Mk2 키나제의 분해제로서 유용한 화합물 및 조성물
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN112029513B (zh) 2012-02-22 2024-02-23 默克专利股份有限公司 液晶介质
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
CN104981791A (zh) * 2012-09-24 2015-10-14 克莱尔蒙特·斯皮德 移动发送方控制的数据访问和数据删除方法和系统
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
US10138256B2 (en) * 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
WO2016044463A3 (en) 2016-09-01
WO2016044463A2 (en) 2016-03-24
AU2015317741A1 (en) 2017-04-20
IL251051A0 (en) 2017-04-30
AU2015317741B2 (en) 2020-01-16
SA517381115B1 (ar) 2021-03-09
IL251051B (en) 2019-11-28
MA40534B1 (fr) 2021-04-30
SI3193611T1 (sl) 2021-08-31
JP2022078315A (ja) 2022-05-24
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
JP7375072B2 (ja) 2023-11-07
MA40534A (fr) 2016-03-24
US11584757B2 (en) 2023-02-21
BR112017005266B1 (pt) 2022-11-01
EP3193611A4 (en) 2018-02-28
EA037299B1 (ru) 2021-03-05
CO2017003279A2 (es) 2017-09-29
TWI744217B (zh) 2021-11-01
EA201790380A1 (ru) 2017-08-31
US9458175B2 (en) 2016-10-04
HUE054347T2 (hu) 2021-08-30
JP2019194236A (ja) 2019-11-07
TW201617351A (zh) 2016-05-16
KR20170063734A (ko) 2017-06-08
US20170114073A1 (en) 2017-04-27
EP3193611A2 (en) 2017-07-26
EP3912981A1 (en) 2021-11-24
NZ730603A (en) 2024-02-23
CA2961607A1 (en) 2016-03-24
CN106998692B (zh) 2020-09-08
LT3193611T (lt) 2021-08-25
US20210053984A1 (en) 2021-02-25
CN106998692A (zh) 2017-08-01
SMT202100311T1 (it) 2021-07-12
MX2017003359A (es) 2017-11-22
SG11201701861RA (en) 2017-04-27
US9790235B2 (en) 2017-10-17
MX373341B (es) 2020-05-26
DK3193611T3 (da) 2021-05-10
MX2020005213A (es) 2020-08-20
EP3193611B1 (en) 2021-03-24
PT3193611T (pt) 2021-05-28
US10577380B2 (en) 2020-03-03
CA2961607C (en) 2023-03-28
PL3193611T3 (pl) 2021-10-04
US10253040B1 (en) 2019-04-09
CL2017000576A1 (es) 2017-12-01
US20160075720A1 (en) 2016-03-17
ECSP17023281A (es) 2017-06-30
JP2017529367A (ja) 2017-10-05
SG10201902326XA (en) 2019-04-29
KR102457848B1 (ko) 2022-10-25
RS62017B1 (sr) 2021-07-30
CY1124215T1 (el) 2022-05-27
US20190375762A1 (en) 2019-12-12
BR112017005266A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
JP7375072B2 (ja) Ｍｋ２阻害剤およびその使用
JP6554507B2 (ja) ヘテロアリール化合物およびそれらの使用
EP3080103B9 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US11098057B2 (en) 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP4308228A1 (en) Plasma kallikrein inhibitors
HK1241225B (en) Mk2 inhibitors and uses thereof
HK1241225A1 (en) Mk2 inhibitors and uses thereof
JP2026503867A (ja) Ｍｋ２阻害剤およびその使用
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190709

R150 Certificate of patent or registration of utility model

Ref document number: 6556225

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250